A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa
Latest Information Update: 30 Nov 2022
At a glance
- Drugs RIX 4414 (Primary) ; Rotavirus vaccine Bio Farma/Murdoch Childrens Research Institute (Primary) ; Rotavirus vaccine PATH (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 31 May 2022 Status changed from recruiting to active, no longer recruiting.